‘New GSK’ Should Consider New CEO Too, Says Activist Investor
Claims Leadership Lacks Credibility
Executive Summary
Elliott Advisors have said more pharma expertise on the board – including a possible new CEO – is the only way for GSK to restore investor confidence.
You may also be interested in...
‘New GSK’ Still Has Some Convincing To Do
Once the consumer health division is spun out in mid-2022, a leaner ‘new GSK’ must set about delivering on its promising pipeline – and proving its skeptics wrong.
Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.
Corbus And Janux Lead Q1’s Small-Cap Winners
Corbus has presence in both antibody drug conjugates and obesity, and was the stand-out small-cap target for investors with a fivefold increase in its share price in Q1.